目的：研究宫颈癌患者血清可溶性Endoglin水平变化及其临床价值。方法应用酶联免疫吸附试验法(ELISA)对31例正常人(正常对照组)及63例宫颈癌患者(宫颈癌组)血清可溶性Endoglin水平进行检测,并比较38例宫颈癌患者根治手术前后血清可溶性Endoglin水平。结果宫颈癌组患者血清可溶性Endoglin水平(5.01±1.03)μg/L明显高于正常对照组(3.57±0.30)μg/L (P<0.01),血清可溶性Endoglin水平与宫颈癌患者临床分期有明显相关,与宫颈癌组患者年龄和病理类型无明显相关；Ⅳ期宫颈癌血清可溶性Endoglin水平(6.41±0.22)μg/L明显高于Ⅲ期(5.25±0.25)μg/L (P<0.01),Ⅲ期血清可溶性Endoglin水平明显高于Ⅱ期(4.38±0.26)μg/L (P<0.01),Ⅱ期血清可溶性Endoglin水平明显高于Ⅰ期(3.68±0.29)μg/L (P<0.05),Ⅰ期血清可溶性Endoglin水平与正常对照组比较,差异无统计学意义(P>0.05),血清可溶性Endoglin在宫颈癌患者根治术后的表达水平(3.85±0.71)μg/L明显低于术前(4.38±0.68)μg/L (P<0.01)。结论血清可溶性Endoglin表达水平可作为反映宫颈癌患者病情、疗效判断和预后评价的一个参考指标。%Objective To research changes of soluble Endoglin level and its clinical significance in cervical cancer patients.MethodsEnzyme-linked immuno sorbent assay (ELISA) was applied for serum soluble Endoglin level detection in 31 normal people (normal control group) and 63 cervical cancer patients (cervical cancer group). Comparison was made on serum soluble Endoglin level in 38 cervical cancer patients before and after radical operation.ResultsCervical cancer patients had much higher serum soluble Endoglin level as (5.01±1.03)μg/L than (3.57±0.30)μg/L of the normal control group (P<0.01). Serum soluble Endoglin level was obviously related with clinical stage of cervical cancer patients, while it has no relationship with age and pathological type of cervical cancer patients. Stage Ⅳ cervical cancer had much higher serum soluble Endoglin level as (6.41±0.22)μg/L than (5.25±0.25)μg/L of stage Ⅲ (P<0.01); stage Ⅲ cervical cancer had much higher serum soluble Endoglin level than (4.38±0.26)μg/L of stage Ⅱ (P<0.01); stage Ⅱ cervical cancer had much higher serum soluble Endoglin level than (3.68 ±0.29)μg/L of stage Ⅰ (P<0.05). The difference of serum soluble Endoglin level between stage Ⅰ and normal control group had no statistical significance (P>0.05). Serum soluble Endoglin level in cervical cancer patients after operation was obviously lower as (3.85±0.71)μg/L than (4.38±0.68)μg/L before operation (P<0.01).ConclusionExpression level of serum soluble Endoglin can be used as a referring index for showing disease status, judging curative effect and evaluating prognosis in cervical cancer patients.
展开▼
